Subscribe or Manage Preferences

ASCO 2014 - Immuno-Oncology

Three PD-1 inhibitors are in midstage clinical development for metastatic melanoma and other solid tumors: nivolumab, pembrolizumab, and pidilizumab (PIDI).
The immune system plays an important role in the development and progression of many cancers, including lung cancer.
Nivolumab (NIV), a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, has demonstrated durable responses and tolerability in patients with previously treated advanced non-small-cell lung cancer (NSCLC).
Although more than 80% of adults with acute lymphoblastic leukemia (ALL) respond to induction chemotherapy with complete clinical remission, up to 50% of these patients relapse with chemoresistant disease.
Cell-based therapies with lymphocytes and antigen-presenting cells are promising approaches in the context of cancer immunotherapy.
Three PD-1 inhibitors are in midstage clinical development for metastatic melanoma and other solid tumors: nivolumab, pembrolizumab (PEM), and pidilizumab.
Ipilimumab (IPI), an anti-CTLA-4 antibody, has become a standard option in the management of advanced melanoma after demonstrating durable responses and improved overall survival (OS).
Uveal melanoma is the most common primary intraocular malignancy in adults. In the United States, approximately 4.3 new cases are diagnosed per 1 million people, with no variation based on geographic latitude.
PD-L1 expression has been observed in most clear cell renal cell carcinoma (RCC) and is associated with poorer cancer-specific survival.
Management of patients with lymph node-positive (high-risk) stage III melanoma is a clinical challenge today. In Europe, high-dose interferon alpha-2b is approved for use in this setting. In the United States, both high-dose interferon alpha-2b and pegylated interferon alpha-2b are registered for patients with high-risk stage III melanoma.
Page 1 of 3
Results 1 - 10 of 22
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology